Pfizer Inc. Forecasted to Earn Q3 2025 Earnings of $0.72 Per Share (NYSE:PFE)

Pfizer Inc. (NYSE:PFE - Free Report) - Equities research analysts at Zacks Research lowered their Q3 2025 earnings per share (EPS) estimates for Pfizer in a research note issued to investors on Monday, September 23rd. Zacks Research analyst K. Shah now expects that the biopharmaceutical company will post earnings of $0.72 per share for the quarter, down from their previous forecast of $0.73. The consensus estimate for Pfizer's current full-year earnings is $2.66 per share.

A number of other analysts also recently commented on the company. UBS Group increased their price target on Pfizer from $30.00 to $31.00 and gave the company a "neutral" rating in a research report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a "neutral" rating to an "outperform" rating and raised their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, September 16th. StockNews.com upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a report on Thursday, August 1st. Finally, Daiwa America upgraded shares of Pfizer from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $34.54.

Pfizer Stock Up 0.2 %

NYSE:PFE traded up $0.06 on Tuesday, hitting $29.37. The stock had a trading volume of 10,836,677 shares, compared to its average volume of 37,723,684. Pfizer has a 1 year low of $25.20 and a 1 year high of $34.11. The firm's fifty day simple moving average is $29.36 and its two-hundred day simple moving average is $28.26. The stock has a market cap of $166.43 billion, a P/E ratio of -492.58, a price-to-earnings-growth ratio of 1.05 and a beta of 0.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.67 EPS.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.72%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer's dividend payout ratio (DPR) is presently -2,799.53%.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Olistico Wealth LLC purchased a new position in Pfizer during the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer in the second quarter worth $29,000. Quarry LP purchased a new stake in shares of Pfizer in the second quarter worth $31,000. Creekmur Asset Management LLC purchased a new position in Pfizer during the fourth quarter worth about $32,000. Finally, Trivant Custom Portfolio Group LLC increased its stake in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 600 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.